Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Burkitt Lymphoma 2Recurrence 1

Interventions

Cyclophosphamide 166Rituximab 155Specimen Handling 114Biopsy 91Magnetic Resonance Spectroscopy 90Vincristine 85Doxorubicin 79Prednisone 78fludarabine 69venetoclax 67obinutuzumab 62ibrutinib 54Lenalidomide 53Dexamethasone 53Cytarabine 47Methotrexate 44acalabrutinib 42Etoposide 41CT-P10 40blinatumomab 38fludarabine phosphate 34Bendamustine Hydrochloride 34prednylidene 32Gemcitabine 32deltacortene 31Calcium Dobesilate 30zanubrutinib 29pembrolizumab 29glofitamab 28Nivolumab 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
CVAD protocol × Lymphoid × 90 days × Clear all
NCT07564453 2026-05-04

FLOW

The First Affiliated Hospital of Soochow University

Phase 2 Recruiting
101 enrolled
Lymphoid

Burkitt Lymphoma

NCT06287229 2026-04-24

Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab

M.D. Anderson Cancer Center

Phase 1/2 Recruiting
40 enrolled
Lymphoid

Burkitt Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡